Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Oxidative stress (OS) in the kidney is considered a key factor driving subsequent pathological events, including cascades of inflammatory and fibrotic responses. Therefore, therapeutic strategies to suppress OS are hypothesized to prevent or mitigate the attenuation of renal fibrosis in chronic kidney disease (CKD). To explore such strategies against OS, we applied “compound X”, a lanthanoid-containing compound with potential antioxidant activity, to renal protection studies. Compound X is stable at room temperature and has the advantage of being easy to handle as a pharmaceutical ingredient. Our preliminary animal study of compound X demonstrated its potent protective effects against renal damage in an adenine-induced renal injury model, suggesting its potential as a promising therapeutic candidate. Therefore, we investigated the effect of compound X on the progression of CKD, employing ferric citrate as a comparison compound.
Male Wistar rats (13 weeks old) were fed a diet containing 0.25% adenine for two weeks to establish an adenine-induced renal injury model. After model establishment, the rats were divided into four groups: 0.25% adenine group (A), 0.25% adenine + 3% ferric citrate group (Fe), 0.25% adenine + 0.64% compound X group (X-L), and 0.25% adenine + 1.29% compound X group (X-H). Each group received the respective diet for 28 days. Blood samples were collected weekly for biochemical analyses. On day 28, the rats were euthanized under anesthesia for pathological examination. All procedures were performed in compliance with the institutional guidelines for animal experiments of the University of Miyazaki (approval number: 2023-41).
The blood biochemical analyses revealed elevations in creatinine and blood urea nitrogen (BUN) levels in all adenine-administered groups. This increase was particularly pronounced in the Fe group, whereas no significant differences were observed among the A, X-L, and X-H groups. Inorganic phosphate levels in the X-L and X-H groups were lower than those in the A and Fe groups. Histopathological examination revealed that the degree of renal cortical fibrosis was milder in the X-L and X-H groups than in the A and Fe groups.
The administration of compound X resulted in a decrease in inorganic phosphate levels and attenuation of renal fibrosis. These findings suggest that compound X has potential as a novel therapeutic candidate not only for CKD but also for other diseases associated with oxidative stress.
